DAXOR CORP (DXR) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Security Holders held on June 23, 2026. Daxor Corporation is a medical instrumentation and biotechnology company focused on blood volume measurement, primarily marketing the FDA-cleared BVA-100 Blood Volume Analyzer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
The following directors were elected for terms expiring in 2027:
- Henry D. Cremisi, MD: 4,436,972 For; 6,563 Withheld
- Edward Feuer: 4,436,972 For; 6,563 Withheld
- Joy Goudie, Esq.: 4,436,972 For; 6,563 Withheld
- Michael Feldschuh: 4,116,310 For; 327,225 Withheld
- Jonathan Feldschuh: 4,111,640 For; 331,895 Withheld
- Caleb DesRosiers, Esq.: 4,436,970 For; 6,565 Withheld
Shareholders ratified Bush & Associates, CPA as the independent registered public accounting firm with 4,423,295 votes For, 19,839 Against, and 401 Abstain.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the impact of hiring sales staff and expanding distribution channels. Management notes that actual results may differ due to risks including post-market clinical data collection, product development, market acceptance, competitive offerings, intellectual property, and FDA regulatory actions.
Investor Verification Checklist
- Verify the specific reasons for the higher "Withheld" votes for directors Michael and Jonathan Feldschuh compared to other nominees.
- Review the company's most recent 10-K or 10-Q for actual financial performance metrics not included in this 8-K.
- Confirm the status of the BVA-100 commercialization and any new FDA regulatory developments.
- Check for any subsequent filings regarding the integration of acquired businesses mentioned in the risk factors.